Our scalable technologies deliver an output range from 3 units per minute to 300 units per minute. This unique offering enables us to manage dynamic client volumes of biopharmaceutical therapies and ultra orphan, niche personalized medicines to large-volume treatments and from clinical development through to commercial launch. Patient-centricity is key during clinical development stages, aiding ease of administration, adherence to therapies and ultimately improving clinical outcomes. At PCI we have over 20 years of experience specialist packaging of advanced drug delivery specialist injectable dosage forms. This combined with industry- leading capabilities in the final assembly, packing and testing of drug device combination products delivers a seamless solution for our global client base. Proving these expert services from early-stage development through to commercial scale launch, we support you at every stage of the product lifecycle and ultimately deliver true speed to market. Advanced Drug Delivery and Drug Device Combination Products
speed to study ™ As pharmaceutical companies seek to streamline early phase development to establish proof of concept quickly and efficiently, PCI’s speed to study TM services are designed to maneuver complex trial designs with maximized flexibility and speed. PCI has invested in global teams, sites and resources to provide time-tested, phase-specific processes, operations and the experts needed to deliver efficiently and cost-effectively. A culture of speed, expertise and flexibility is key to ensuring that early phase studies are initiated without delay and correctly from the start. PCI offers speed to study TM , a service combining an experienced team of manufacturing, packaging, labeling and global distribution specialists with expertise in early phase studies delivering maximum efficiency.
13
Together, delivering life changing therapies.
PCI Pharma Services
12
Powered by FlippingBook